92 RESULTS
COMMENT Using low-intensity ultrasound to deliver anti-Aβ antibodies to the brain is indeed a promising strategy to increase antibody levels in the brain (and reduce ARIA). We have shown previously that ultrasound achieves a fivefold increased brain uptake of an
COMMENT The work by Fowler and colleagues is beautiful, and the images visualizing tau filaments within extracellular vesicles by cryo-electron microscopy are simply stunning. I had always asked myself what would confer seeding capability to extracellular vesicle
COMMENT This is very sad to hear. I am a co-author on one of the papers in question (Amar et al., 2017). Sylvain had reached out to me at the time, as we had just made tau-isoform-specific antibodies. As a collaborator, whether blots are manipulated is generally
COMMENT It is very sad to learn that John has passed away. It was via Michel Goedert (who had initiated a collaboration with Kurt Bürki’s team at Novartis back in 1992) that I got to know both John and Virginia at a stage when I had entered the AD space, coming f
COMMENT Using a mass-cytometry–based method, synaptometry by time of flight (SynTOF), this study focuses on the synapse to uncover what causes AD. I generally like this elegant approach, but believe it adds an additional variable compared to more classical mass-s
COMMENT In our view, for a tau antibody to work, there are four major hurdles to overcome: (i) the blood-brain barrier, given that only an estimated 0.1 percent of peripherally administered therapeutic antibodies enter the brain; (ii) the plasma membrane of neuro
COMMENT Understanding the role of the isotype in developing antibody therapies for Alzheimer’s disease is indeed critical. The work from our group also supports the use of tau antibodies in an IgG4 (low effector function) isotype in clinical trials. In a direct c
COMMENT Interestingly, while many studies reveal that pathological changes of Aβ and tau, including their aggregation into oligomers and fibrils, can lead to mitochondrial dysfunction, a similar causality cannot be easily established for mitochondrial dysfunction
COMMENT I find the work of Tony Wyss-Coray’s laboratory absolutely fascinating. It reveals a differentiated look at the BBB and how it changes under conditions of physiological aging. It is very relevant for our work. Many labs, including ours, aim to use therape
COMMENT A major challenge in treating brain diseases is presented by the blood-brain barrier (BBB), which constitutes an efficient barrier not only for toxins but also a wide range of therapeutic agents. In overcoming this impediment, ultrasound in combination wi
COMMENT We would like to contribute to the discussion about blood-borne factors entering the brain, with the two STM studies reporting that age-related impairments in the BBB allow for an influx of albumin into the brain, activating TGFβ receptors, overexciting n
COMMENT Both studies elegantly identify novel interactions between tau and microtubules (MTs) in a physiological setting, either in regulating tau condensation or in protecting MTs from depolymerizing. I have been reminded of a paper from the Safinya lab on the r
COMMENT We share the view of Drs. Tapias and Beal that misfolded proteins such as Aβ and tau impair all aspects of mitochondrial functions. In fact, we have a long-standing interest in how Aβ and tau impair neuronal functions, dating back to 2005 when we combined
COMMENT I really liked this study, which elegantly combines work in human and transgenic tissue, in vitro and in primary cultures. The human brain and doxycycline rescue experiments in rTg4510 mice are especially compelling. I think the question (admittedly a dif
COMMENT This is a very interesting paper. In her news piece Madolyn Rogers writes “It is unclear how the antibodies enter the brain. The authors found no breach of the blood-brain barrier, but did see the antibody accumulate in the choroid plexus of 5xFAD mice, h
